This Week in RadOnc - First Edition - October 1st, 2026


First Edition - October 1st, 2026

Welcome to the first edition of This Week in Rad Onc, affectionately known as TWiRO.

My name is Michael Owens. After attending ASTRO for the tenth time this year, I spoke with several colleagues who hadn't heard some of the biggest clinical and industry news announced at the meeting. It made me realize there was a need for a consolidated, trusted source covering both the clinical and industry developments that matter to those of us working in and around the radiation oncology clinic.

Since this is the first edition, I also wanted to introduce myself to those of you who don't already know me—and provide a little disclosure about where I'm coming from.

I've spent more than a decade as one of the core inventors and the principal designer of the RefleXion radiotherapy system, the first biology-guided radiotherapy platform that uses real-time PET signals to autonomously account for tumor motion during treatment. I'm also an advisor to several radiation oncology startups, such as MedLever and a stealth startup working on a novel product and platform in the space.

TWiRO is editorially independent of those professional roles. Nothing published here represents the opinions of my employers, clients, collaborators, or the companies I advise. My goal is to make this a vendor-neutral roundup of the most important clinical, scientific, and industry news in radiation oncology each week. I'll work to be transparent about potential conflicts and to separate reporting from my own analysis and commentary.

Cancer doesn't care what company you work for or what hospital you practice at. Neither does this newsletter.

I also hope to bring something else to TWiRO: the perspective of both a caregiver and a patient.

In 2025, my wife was diagnosed with triple-negative breast cancer and went through months of surgery, chemotherapy, and radiotherapy. Less than four months after her treatment concluded, in August 2026, I was diagnosed with HPV-positive oropharyngeal squamous cell carcinoma.

As I write this first editor's note, I'm sitting at Dana-Farber Cancer Institute, halfway through my own course of radiotherapy and chemotherapy.

That experience has given me an even greater appreciation for how the technologies, research, clinical decisions, and businesses we discuss in this field ultimately affect the people sitting on the other side of the treatment-room door.

Thank you for signing up for This Week in RadOnc. My hope is that by making it easier to keep up with what's happening across our field—and by sharing that knowledge with one another—we can help improve cancer care, because as G.I. Joe taught an entire generation of us: “Knowing is half the battle.”

With that in mind, let's begin.

Best,

Michael K Owens​
Editor-in-Chief
​This Week in RadOnc


Table of Contents

  1. Takeaways of the Week: Links to some of the big takeaways from the past week.
  2. Notable Publications: Key findings from influential open-access research and conference abstracts shaping radiation oncology practice.
  3. Industry Updates: The latest developments in technology, regulation, reimbursement, and the business of radiation oncology.
  4. Spotlight on Patient Care: A closer look at a publicly shared clinical case or trial dataset, highlighting treatment approaches and reported outcomes.
  5. Clinical Trials to Watch: Recruiting and upcoming studies exploring new radiation oncology treatments, with key eligibility and participation details.
  6. Upcoming Events: A listing of upcoming professional society events, radiation oncology symposia, patient advocacy events, and cancer awareness events.

Takeaways of the Week

  • Postoperative brain SRS: Alliance A071801 strengthens the case for fractionation after resection of larger metastases, with improved surgical-bed control. ASTRO 2026​
  • SCLC brain metastases: NRG-CC009’s survival signal favors SRS, but its primary neurocognitive endpoint was negative. ASTRO 2026​
  • Postprostatectomy hypofractionation: Five-year GU003 patient-reported outcomes are reassuring, but higher clinician-reported grade 3 urinary toxicity deserves attention. ASTRO 2026​
  • Protons for HCC: NRG-GI003 crossed its interim futility boundary for an overall-survival advantage; neither equivalence nor harm is established. ASTRO 2026​
  • Lower treatment burden: Pancreatic SBRT and response-adapted 4-Gy myeloma palliation appear promising, but limitations may prevent wide adoption. ASTRO 2026​
  • For therapists and physicists: New evidence supports careful breast DIBH implementation and practical dermatitis prevention; surface guidance still requires appropriate internal verification. frontiersin.org​
  • The new Accela LINAC was announced: The fastest radiotherapy delivery to date is coming; Accela is 510(k)-pending and unavailable for sale. siemens-healthineers.com​
  • Access and reimbursement: ASTRO is pressing CMS on proposed 2027 payment changes. The society’s recommendations are advocacy positions, not final payment policy. American Society for Radiation Oncology (ASTRO)​

Academic Publication Review

This week, our selection includes two breaking papers, three papers from the past month, three from earlier this year, and six ASTRO 2026 abstracts. Conference findings remain preliminary. Public abstract access does not confer an open reuse license.

1. Acute toxicity and patient-reported quality of life during daily online adaptive radiotherapy versus conventional IGRT for localized prostate cancer: a prospective parallel cohort study​
Goda Kalinauskaite, Luise A. Künzel, Kerstin Rubarth et al. Strahlentherapie und Onkologie, 2026-09-25. DOI · Open full text, CC BY 4.0.
​Keywords: adaptation, toxicity, quality of life.

In 74 patients receiving 20-fraction treatment, daily adaptation was associated with lower maximum gastrointestinal toxicity and favorable patient-reported symptoms. Genitourinary toxicity was similar. Nonrandom allocation and baseline differences limit causal interpretation; this is an encouraging clinical signal for randomized evaluation.

2. Microwave ablation versus stereotactic body radiotherapy for oligometastatic colorectal liver metastases: LAVA-CRLM​
Signe Lenora Risumlund, Line Bjerregaard Stick, Ane Appelt et al. The Lancet Regional Health–Europe, online 2026-09-25. DOI/open article, CC BY-NC-ND 4.0.
​Keywords: SBRT, liver metastases, ablation.

One-year freedom from local progression was 77.7% with microwave ablation and 83.0% with SBRT, without a significant difference. Grade ≥2 treatment-related toxicity was 25% versus 3%. The wide efficacy confidence interval prevents an equivalence claim, but the findings strengthen multidisciplinary consideration of SBRT.

3. StrataXRT Versus Mepitel Film for Prevention of Acute Radiation Dermatitis in Postmastectomy Radiotherapy​
Shing Fung Lee, Patries M. Herst, Melissa L. James et al. Journal of Medical Radiation Sciences, 2026-09-11. DOI · Open full text, CC BY-NC 4.0.
​Keywords: dermatitis, Mepitel Film, skin care.

A pooled randomized, split-chest-wall comparison in 120 patients favored Mepitel Film for grade 2–3 dermatitis. Severe dermatitis and moist-desquamation differences were not significant. The study offers immediately relevant evidence for therapist and nursing protocols, alongside application burden and patient preferences.

4. Surface-guided deep-inspiration breath-hold radiotherapy for left-sided breast cancer: systematic review and meta-analysis​
Xiaoyan Wu, Huaqiong Wang, Peng Wu and Yin Zhang. Frontiers in Oncology, 2026-09-17. DOI · Open full text, CC BY 4.0.
​Keywords: SGRT, DIBH, verification.

Across 52 studies, SGRT-assisted DIBH reduced cardiac and ipsilateral-lung doses compared with free breathing; pooled mean heart dose decreased approximately 1.21 Gy. Setup comparisons did not establish equivalence. Appropriate internal imaging remains necessary because external surface position is a surrogate for internal anatomy.

5. CCTG BR38: Randomized Phase III Trial of Consolidative Use of Radiotherapy to Block Oligoprogression in Metastatic NSCLC​
C. Jillian Tsai, Alexander Sun, Penelope A. Bradbury et al. JCO Oncology Advances, 2026-09-17. DOI/open article​
​Keywords: CURB2, oligoprogression, immunotherapy.

BR38/CURB2 tests ablative radiation during first-line immunotherapy-based treatment for metastatic NSCLC. This is a protocol publication, with no efficacy results. Its value is the definitive research question and active enrollment opportunity. The earlier ASCO protocol abstract is deliberately not counted separately.

6. Definitive IMRT alone with reduced prophylactic nodal irradiation for early-stage oropharyngeal cancer: JCOG1208​
Satoaki Nakamura, Takeshi Kodaira, Ryunosuke Machida et al. Radiotherapy and Oncology, online 2026-06-28. DOI · Open full text, CC BY-NC-ND 4.0.
​Keywords: IMRT, elective nodes, de-escalation.

This single-arm study treated 57 selected T1–2N0–1 patients under seventh-edition staging. Three-year survival was 93%, with no isolated failures in omitted elective nodal areas. The results justify further study of volume reduction, without supporting general de-escalation across all HPV-associated disease.

7. The survival impact of combining radiotherapy and immune checkpoint inhibitors in solid tumors: a systematic review and living meta-analysis​
Mathijs L. Tomassen, Claudia E. Pronk, Eric Deutsch et al. European Journal of Cancer, online 2026-05-25. DOI · Open full text, CC BY 4.0.
​Keywords: sequencing, immunotherapy, meta-analysis.

Across 41 randomized trials and 15,049 patients, adding checkpoint inhibition did not significantly improve overall survival across every included setting. Progression endpoints and some subgroups favored combination therapy. Disease site and sequencing matter; most included trials tested adding immunotherapy, not adding radiation.

8. Neoadjuvant SBRT with durvalumab and oleclumab in ER-positive/HER2-negative breast cancer: Neo-CheckRay​
Alex De Caluwé, Isabelle Desmoulins, Kim Cao et al. Nature Medicine, 2026-06-25. DOI · Open full text, CC BY 4.0.
​Keywords: Neo-CheckRay, immunotherapy, SBRT.

Among 147 patients receiving chemotherapy and SBRT, adding durvalumab with or without oleclumab did not significantly improve the primary residual-cancer-burden endpoint. Pathologic-response and immune-biomarker signals warrant further research, particularly in PD-L1-negative tumors, but do not establish a new treatment standard.

9. Alliance A071801: postoperative single-fraction versus fractionated SRS​
Paul D. Brown, Karla Ballman, Ayal Aizer et al. 2026-09-28, LBA01. Public abstract.​
Keywords: fractionation, local control, A071801.

Fractionated SRS improved one-year surgical-bed control to 87% versus 81% after a single fraction. Survival also favored fractionation, but was a secondary and unexpected finding. Radiation-necrosis rates did not differ significantly. These results strengthen fractionation discussions after resection of larger metastases.

10. NRG-CC009: SRS versus hippocampal-avoidant WBRT plus memantine​
Chad G. Rusthoven, R. Paulus, Vinai Gondi et al. 2026-09-28, LBA02. Public abstract.
​Keywords: SCLC, SRS, neurocognition.

The primary time-to-neurocognitive-failure endpoint was not significantly improved with SRS. Median survival favored SRS, 17.4 versus 8.6 months, in a secondary analysis. The result is consequential, but requires discussion of the negative primary endpoint and careful intracranial surveillance.

11. SOFT Preop: SBRT versus conventional preoperative pancreatic chemoradiation​
William A. Hall, S. Tsai, A. Banerjee et al. 2026-09-29, LBA08; findings publicly released September 28. Public abstract.
​Keywords: pancreas, SBRT, quality of life.

Pathologic nodal positivity was similar, while physical-function and fatigue measures favored the shorter course. Survival differences were not statistically significant, and the trial was not designed to establish survival equivalence. The findings support further evaluation of lower-burden preoperative treatment.

12. Ultralow-dose, response-adapted radiotherapy for symptomatic multiple myeloma​
Leslie K. Ballas, A. A. Garsa Jr, Z. He et al. 2026-09-27, abstract 10. Public abstract.
​Keywords: palliation, myeloma, retreatment.

Updated investigator data in ASTRO’s release reported pain responses of 66% at four weeks and 86% at six months among questionnaire respondents; 19% needed retreatment. These updated figures supersede the abstract’s earlier values. Patient selection and response denominators are essential to interpretation.

13. NRG-GI003: protons versus photons for hepatocellular carcinoma​
Theodore S. Hong, K. Winter, E. J. Koay et al. 2026-09-28, abstract 2. Public abstract.
​Keywords: protons, HCC, randomized evidence.

The trial crossed its interim futility boundary for an overall-survival benefit from protons. Among 115 eligible patients, the survival hazard ratio was 1.30 with a wide 90% confidence interval of 0.83–2.04. A numerical toxicity advantage was not significant. Neither equivalence nor proton-related harm is established.

14. NRG-GU003: five-year hypofractionated versus conventional postprostatectomy RT​
Mark K. Buyyounouski, M. Borges, Ronald C. Chen et al. 2026-09-27, abstract 7, IJROBP supplement. DOI · Public abstract​
​Keywords: hypofractionation, GU003, late toxicity.

Five-year urinary and bowel patient-reported outcomes were comparable, without a significant biochemical-failure difference. However, grade 3 genitourinary toxicity was 13% versus 3%, favoring conventional fractionation. Five-year questionnaire completion was 56%. The shorter course should be discussed alongside this late-toxicity signal.


Industry Updates

Siemens Healthineers/Varian — Accela and NeoArc​
​2026-09-27 | Company press release | Treatment delivery​
​Keywords: Accela, NeoArc, DMAT.​
The company introduced Accela around dynamic modulated arc therapy, claiming single-breath-hold stereotactic delivery and multisite SBRT in as little as 60 seconds. These are manufacturer claims. The regulatory footnote states 510(k) pending and unavailable for sale in any market. Official announcement.

Elekta — Adaptive workflows across the portfolio​
​2026-09-27 | Company press release | Adaptive RT and brachytherapy
​
Keywords: adaptation, Elekta, brachytherapy.​
Elekta announced developments spanning MR- and CT-guided radiotherapy, Gamma Knife and brachytherapy, including Harmony adaptation and Prostate Guideway. Availability varies by market. Prostate Guideway remains precommercial, with FDA clearance and EU CE marking pending. Official announcement.

GE HealthCare/Mass General Brigham — Generative-AI research​
​2026-09-23 | Company press release | Research partnership
​
Keywords: generative AI, interoperability, workflow.​
The collaboration will explore AI tools that help teams retrieve and interpret planning and treatment information spread across systems. This is a research announcement; it does not establish a cleared clinical product or demonstrated patient benefit. Official announcement.

ASTRO — Comments on proposed 2027 Medicare payments​
​2026-09-14 | Official society statement | Reimbursement and access​
ASTRO urges CMS to correct a hospital payment assignment the society says undervalues commonly delivered treatment and affects freestanding centers. It also requests caution on broader methodology changes. These are recommendations responding to proposed rules, not finalized payment changes. Official statement.
​Keywords: Medicare, reimbursement, access.

ASTRO — First radiation-therapy guideline spanning bladder cancer care​
​2026-09-16 | Official society announcement | Clinical guideline​
​Keywords: bladder preservation, guideline, trimodal therapy.​
The guideline supports trimodal therapy as a curative option for appropriately selected muscle-invasive disease and addresses postoperative and metastatic settings. Multidisciplinary teams should review selection and delivery pathways together. The paper appeared online September 15. Guideline resources.

Sun Nuclear — AdaptCHECK interoperability with Accela​
​2026-09-27 | Company press release | Medical-physics QA
​
Keywords: adaptive QA, AdaptCHECK, interoperability.
Sun Nuclear reports validation with technical and clinical partners for secondary calculations, adaptive-plan recalculation and log-file monitoring. This manufacturer-reported interoperability does not replace local commissioning. The associated Accela system remains clearance-pending. Official announcement.


Spotlight on Patient Care

RTOG 0617: learning from a deidentified radiation-planning archive

Trial summary: RTOG 0617 (NRG trial profile) randomized unresectable stage III NSCLC to 60 versus 74 Gy with carboplatin/paclitaxel, with or without cetuximab. Uniform dose escalation did not improve survival. The archive enables retrospective investigation of planning, dose distribution and toxicity.

The NSCLC-Cetuximab collection contains 490 deidentified participants, with DICOM CT, RTSTRUCT, RTPLAN and RTDOSE. Dates are modified while preserving longitudinal relationships. This is a dataset spotlight; no individual patient’s images or linked outcome are presented.

Investigator: NRG identifies Jeffrey D. Bradley, MD, as principal investigator. He led the trial’s primary publication, which listed Washington University as his affiliation at that time.

Planning lesson: The trial compared conformal 60-Gy and 74-Gy schedules. After obtaining C;access, teams could examine target coverage against heart and lung exposure using the archived contours and dose. That is a proposed educational exercise, not an assessment of an individual delivered plan.

Reported outcome: Trial-level median survival was 28.7 months with 60 Gy versus 20.3 months with 74 Gy. These aggregate results must not be attributed to a selected archive patient. Report on PubMed.

Access and license: This is limited-access, not unrestricted open data. An NCTN/NCORP Data Archive request for NCT00533949, including imaging, and the applicable collaborative agreement are required. Downloads use NBIA Data Retriever and the dataset lives at The Cancer Imaging Archive.


Clinical Trials to Watch

Registry status was checked 2026-09-29 through ClinicalTrials.gov. The tracker includes sponsor-reported update dates, fuller eligibility, recruiting-site examples and study links. Eligibility below is approximate; overall recruitment does not imply every listed site is open.

Clinical Trial

Details

Summary

Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer (CURB2)

​CURB2/BR38, NCT06686771​

Canadian Cancer Trials Group

Recruiting; Canada and U.S.

Lung - Phase III

Metastatic NSCLC with oligoprogression during first-line immunotherapy ± chemotherapy. Tests ablative RT to progressing lesions alongside systemic treatment versus usual systemic management.

Proton Beam Radiation Therapy After Treatment for Resected N2 Non-Small Cell Lung Cancer

​NCT06008730​

Emory University

Recruiting; Winship, Atlanta

Lung - Phase II

Adults with complete resection after preoperative systemic therapy but residual pN2 disease. Evaluates postoperative proton RT in a population with difficult locoregional-control decisions.

Testing Repeat Radiation Therapy for Recurrent Non-small Cell Lung Cancer (NRG-LU011)

​NCT07835789​

NRG Oncology

Recruiting; Not yet recruiting, estimated start 2026-12-18

Lung - Phase I

Selected locoregional NSCLC recurrence after prior definitive RT, without distant metastases. Compares repeat thoracic radiation with standard systemic therapy.

A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)

​NCT05417516​

Ontario Clinical Oncology Group

Recruiting; Canada and Australia

Breast - Phase III

Women ≥50 with node-negative invasive tumors ≤3 cm after lumpectomy and clear margins. Compares five-fraction partial-breast with five-fraction whole-breast irradiation.

Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer (TAORMINA)

​NCT05377047​

Västra Götaland Region

Recruiting; Sweden, Norway, Ireland, Italy, Slovenia and Israel

Breast - Phase III

Breast cancer with 1–5 metastases in at most two organs and controlled primary disease. Tests SABR added to first-line systemic treatment.

Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION)

​NCT07513389​

Medical University of South Carolina
​Recruiting: Charleston, SC
​
Head and Neck - Phase II

Selected HPV-associated oropharyngeal cancer after transoral surgery, favorable pathology and negative postoperative circulating HPV DNA. Studies RT omission under biomarker surveillance; this remains experimental.

Adaptive Versus Non-adaptive Radiotherapy and 2 Bladder Filling Instructions for Patients With Intermediate or High Risk Localized Prostate Cancer (ARP)
​NCT06678126​

Scott Tyldesley
​Recruiting: BC Cancer, Vancouver, Canada​
Prostate – Phase II

Intermediate/high-risk cN0M0 prostate cancer receiving 20-fraction prostate/pelvic treatment. Evaluates daily online adaptation and bladder-preparation approaches.

PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer
​NCT07234981​

University of Nebraska
​Recruiting: Omaha, NE​
Prostate – Phase II

Postprostatectomy biochemical recurrence with a targetable PSMA-PET or MRI pelvic/prostate-bed lesion and no distant metastases. Studies image-guided salvage RT with selective boost and ADT.

Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial
​NCT06593431​

MD Anderson Cancer Center
​Recruiting: Houston and Dallas, TX; Camden and Voorhees, NJ​
Pancreas – Phase III

Pancreatic adenocarcinoma with 1–5 metastases, all amenable to local treatment. Tests comprehensive metastasis-directed treatment plus systemic therapy; RT is one permitted local modality.

Simultaneous Boost in Neoadjuvant Radiotherapy for Rectal Cancer
​NCT07200141​

Peking Union Medical College Hospital
​Recruiting: Beijing, China​
Rectum – Phase II

Adults 18–79 with locally advanced, nonmetastatic rectal cancer. Compares a 58.75-Gy versus 50-Gy tumor dose in 25 fractions with chemotherapy and subsequent response assessment.

Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
​NCT07195591​

GT Medical Technologies, Inc.
​Recruiting: 12 United States sites​
CNS / Glioblastoma – Phase III

Resectable newly diagnosed glioblastoma, KPS ≥70. Compares GammaTile at surgery followed by 20-fraction EBRT/TMZ against surgery and standard 30-fraction chemoradiation.

Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT)
​NCT07227610​

Medical University of South Carolina
​Recruiting: Charleston, SC​
CNS / Brain Metastases – Phase II

Adults with neurologically stable 2–5-cm brain metastases and KPS ≥60. Compares staged SRS with fractionated stereotactic RT for large intact lesions.

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
​NCT07061977​

National Cancer Institute
​Recruiting: United States and Puerto Rico​
Cervix – Phase III

Newly diagnosed T3–4 cervical cancer. Tests induction carboplatin/paclitaxel/pembrolizumab before chemoradiation against a standard chemoradiation and pembrolizumab backbone.

Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial Cancer
​NCT07831902​

University College London
​Recruiting: United Kingdom​
Endometrium – Phase III

Completely resected, ER-positive NSMP endometrial cancer with specified high-risk stage II/III features. Compares RT followed by progestin with RT plus chemotherapy.

Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi
​NCT05929222​

Fondazione Italiana Linfomi
​Recruiting: Italy​
Hematologic / Follicular Lymphoma – Phase III

Untreated, non-bulky early-stage grade 1–3A follicular lymphoma suitable for localized RT. Tests adding obinutuzumab to radiation.

PET Guided Dose Reduction for Involved Site Radiotherapy In Early Stage Unfavorable Hodgkin Lymphoma
​NCT07256158​

Fondazione Italiana Linfomi
​Recruiting: Torino, Italy; other listed sites not yet marked open​
Hematologic / Hodgkin Lymphoma – Phase III

Early unfavorable Hodgkin lymphoma with complete metabolic response after initial ABVD. Compares 20-Gy and 30-Gy consolidation after four total chemotherapy cycles.

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
​NCT05382338​

Children’s Oncology Group
​Recruiting: United States and Canada​
Pediatric CNS / Medulloblastoma – Phase III

Ages 4–21 with centrally reviewed low/average-risk medulloblastoma. Integrates sodium-thiosulfate hearing protection and risk-adapted therapy, including reduced radiation for selected low-risk disease.

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
​NCT06239272​

St. Jude Children’s Research Hospital
​Recruiting: seven United States sites​
Pediatric / Young Adult Soft-Tissue Sarcoma – Phase I/II

Ages 1–30 with non-rhabdomyosarcoma soft-tissue sarcoma. Evaluates risk-adapted systemic therapy and limited-margin/dose-escalated RT. Not every participant receives radiation.

Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall
​NCT07823491​

Ohio State University Comprehensive Cancer Center
​Not yet recruiting: Columbus, OH listed; estimated opening December 1, 2026​
Soft-Tissue Sarcoma – Phase III

Resectable grade 3 extremity/trunk UPS or liposarcoma ≥5 cm. Tests chemotherapy intensification alongside pembrolizumab, preoperative RT and surgery.

Phase II Trial Comparing Stereotactic Body Radiotherapy Versus Active Surveillance for Oligometastatic Adenoid Cystic Carcinoma
​NCT07845097​

All India Institute of Medical Sciences
​Not yet recruiting: estimated opening December 20, 2026; locations not posted​
Adenoid Cystic Carcinoma – Phase II

Adenoid cystic carcinoma with controlled primary and 1–5 treatable extracranial metastases. Compares SABR to all sites with active surveillance.


Did you know?

The “gray” honors a person. The absorbed-dose unit is named after physicist Louis Harold Gray, whose work helped establish the foundations of radiation physics and radiobiology.

He developed the basis for the cavity ionization method of measuring dose absorption called the Bragg-Gray equation alongside Sir William Lawrence Bragg. Later, he developed the concept of Relative Biological Effectiveness, a core concept still used in the radiobiology of radiation oncology today.


A Final Note

Thank you for joining us for this roundup of all things radiation oncology this week. If you found one portion of the newsletter more useful than others or have any feedback about what kind of content we could include, we'd love to hear more from you. You can provide us with any feedback about the content of the newsletter, submit content you'd like to see in the newsletter, or just say hi by sending an email to thisweekinradonc@gmail.com

Best,

This Week in RadOnc

This Week in RadOnc is your weekly guide to the research, technology, and industry developments shaping radiation oncology curated for clinicians, technologists, and industry professionals.

Read more from This Week in RadOnc

Volume 3, October 16th, 2026 Welcome back to This Week in Rad Onc! This week’s evidence asks where precision adds value—and where promising technology still needs validation. ROAM strengthens the discussion of postoperative radiation for atypical meningioma, while ASTRO updates bring longer follow-up and important cautions about toxicity, crossover and local control. For treatment teams, new CBCT and electron-dosimetry studies sit alongside practical motion-management guidance. We also...

Volume 2, October 1st, 2026 Welcome back to This Week in Rad Onc! This week, we continue unpacking ASTRO’s findings, with a focus on shorter treatment courses, patient experience, and the evidence needed to bring new approaches into everyday practice. I’m particularly interested in how these developments affect the entire care team and patient outcomes. Alongside the research, you’ll find industry and reimbursement updates, a case spotlight, and recruiting trials in a more accessible format....